Premium
Botox rechallenge—An additional tool in the management of an incompletely emptying bladder and inadequate overactive symptom control following sacral neuromodulation
Author(s) -
Timm Brennan,
Jayarajan Jyotsna,
Chan Garson,
Bolton Damien
Publication year - 2021
Publication title -
luts: lower urinary tract symptoms
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.451
H-Index - 15
eISSN - 1757-5672
pISSN - 1757-5664
DOI - 10.1111/luts.12332
Subject(s) - medicine , overactive bladder , sacral nerve stimulation , urinary retention , neuromodulation , urology , urge incontinence , refractory (planetary science) , urinary incontinence , urinary system , cohort , surgery , stimulation , physics , alternative medicine , pathology , astrobiology
Two female patients aged 70 and 72 with video‐urodynamics‐confirmed detrusor overactivity and detrusor underactivity (DO‐DU) were treated. Patients were refractory to medical therapies and had previously failed intravesical botulinum toxin type A (BoNT‐A) at other centers secondary to urinary retention and difficulty with self‐catheterization. Placement of an Interstim II device (Medtronic, Minneapolis, Minnesota) for sacral neuromodulation (SNM) as alternative third‐line treatment partially improved overactive bladder (OAB) symptoms while significantly improving voiding symptoms. Postvoid residual (PVR) of patients improved from a median of 118 mL (110‐125 mL) to 20 mL (18‐26 mL) and 213 mL (195‐230 mL) to 70 mL (60‐73 mL), respectively. Addition of medical therapies post SNM failed to modify OAB symptoms further and a rechallenge with dose‐reduced BoNT‐A was undertaken.OAB symptoms were significantly improved by addition of BoNT‐A, while urinary retention was avoided (median PVR post BoNT‐A 38 mL [34‐40 mL] and 185 mL [150‐205 mL], respectively). Reduction in incontinence pad use as well as resolution of nighttime incontinence in both patients and daytime incontinence in one patient was achieved. DO‐DU patients treated by SNM who have improved bladder emptying (PVR <100 mL) but incomplete resolution of OAB symptoms should be trialed on adjunct medical therapies to improve OAB symptoms. If OAB symptoms are still inadequately controlled, consideration of a rechallenge with BoNT‐A, particularly with dose reduction, appears to be efficacious and avoids symptomatic retention in this challenging cohort.